Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/nrc3748 http://scihub22266oqcxt.onion/10.1038/nrc3748 C4480224!4480224 !24898058     free     free     free Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\24898058 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Nat+Rev+Cancer 2014 ; 14 (7 ): 502-9 Nephropedia Template TP {{tp|p=24898058 |t=2014. New PARP targets for cancer therapy |pdf=|usr=}}{{24898058 }} gab.com Text New PARP targets for cancer therapy JO: Nat Rev Cancer http://www.kidney.de/pget.php?&tw=1&pmid=24898058 #FOAvip Poly(ADP-ribose) polymerases (PARPs) modify target proteins post-translationally with poly(ADP-ribose) (PAR) or mono(ADP-ribose) (MAR) using NAD(+) as substrate. The best-studied PARPs generate PAR modifications and include PARP1 and the tankyrase PARP5A, both of which are targets for cancer therapy with inhibitors in either clinical trials or preclinical development. There are 15 additional PARPs, most of which modify proteins with MAR, and their biology is less well understood. Recent data identify potentially cancer-relevant functions for these PARPs, which indicates that we need to understand more about these PARPs to effectively target them. Twit Text FOAVip New PARP targets for cancer therapy ????Nat Rev Cancer http://www.kidney.de/pget.php?&tw=1&pmid=24898058 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24898058 #FOAvip English Wikipedia <ref>{{Cite pmid|24898058 }}</ref> New PARP targets for cancer therapy #MMPMID24898058 Vyas S ; Chang P Nat Rev Cancer 2014[Jul]; 14 (7 ): 502-9 PMID24898058 show ga Poly(ADP-ribose) polymerases (PARPs) modify target proteins post-translationally with poly(ADP-ribose) (PAR) or mono(ADP-ribose) (MAR) using NAD(+) as substrate. The best-studied PARPs generate PAR modifications and include PARP1 and the tankyrase PARP5A, both of which are targets for cancer therapy with inhibitors in either clinical trials or preclinical development. There are 15 additional PARPs, most of which modify proteins with MAR, and their biology is less well understood. Recent data identify potentially cancer-relevant functions for these PARPs, which indicates that we need to understand more about these PARPs to effectively target them. |Adenosine Diphosphate Ribose/chemistry/metabolism [MESH] |Animals [MESH] |Humans [MESH] |Neoplasms/*drug therapy/*enzymology/genetics [MESH] |Poly Adenosine Diphosphate Ribose/chemistry/metabolism [MESH] |Poly(ADP-ribose) Polymerase Inhibitors [MESH] |Poly(ADP-ribose) Polymerases/chemistry/genetics/*metabolism [MESH]New PARP targets for cancer therapy (epmc).pdf DeepDyve Pubget Overpricing